BioSpace News Archive

Genetown

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™

Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for BYOOVIZ™, a biosimilar candidate referencing Lucentis®1 (ranibizumab), also known as SB11.

June 25, 2021
·
7 min read
Drug Development

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

Arrowhead Pharmaceuticals, Inc. today presented preclinical data on the development of ARO-DUX4.

June 25, 2021
·
6 min read
BioMidwest

M6P Therapeutics to Participate in Upcoming Fireside Chat Discussing the Company’s First-in-Class Platform for Lysosomal Enzyme and Gene Delivery at the ROTH Virtual Private Company Forum

M6P Therapeutics will participate in a fireside chat at the ROTH Virtual Private Company Forum.

June 25, 2021
·
2 min read
Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity for Xywav.

June 25, 2021
·
12 min read
Biotech Beach

BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®Chairman Terren Peizer discusses BioVie’s late-stage drug pipeline with multiple shots on goal

BioVie Inc. today announced an interview with Terren Peizer, Chairman, that will air on The RedChip Money Report ® on the Bloomberg Network in the U.S. on this coming Saturday, June 26th, at 7 p.m. local time in 73 million homes across the United States.

June 25, 2021
·
3 min read
Business

MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union

June 25, 2021
·
11 min read
BioCapital

CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting

CEL-SCI Corporation invites participants to pre-submit questions for the Company’s upcoming Annual Shareholder Meeting to be held on July 1, 2021 at 10:00 a.m. EDT.

June 25, 2021
·
3 min read